Clinical characteristics and outcome of non-acute myocardial syndrome cardiogenic shock in comparison to its ischaemic aetiology

Abstract Funding Acknowledgements None. Background The mortality in cardiogenic shock (CS) remains high but the report mostly concerns CS in the course of acute myocardial syndrome (ACS). There is limited data about non- ischaemic CS. Purpose The aim of this study was to analyse the clinical characteristics, treatments and outcomes in patients with non-ACS CS in comparison to ischemic aetiology CS. Methods 80 patients with an average age of 62 ± 13 years (81 % male) with CS admitted in 2021 and 2022 to tertiary hospital were divided into 2 subgroups: non-acute myocardial infarction cardiogenic shock (non-ACS-CS) consisted of 16 individuals (20%) and CS in the course of ACS (ACS-CS) consisted of 64 (80%) individuals. The main cause of CS in non-ACS group was worsening of previously diagnosed heart failure 11 (14%). Results Patients from non-ACS group were younger 52±16 vs. 65±11 years old, p=0.005. There were no differences in baseline heart rate 90 72;100 vs. 95 80;107 beats per minute and mean artery pressure 89 73;97 vs. 80 70;97 mmHg for non-ACS-CS vs. ACS-CS, respectively all p0.05. Patients from non-ACS-CS group had lower baseline troponin level 0.29 0.04;0.96 vs. 7.05 0.69;57.4 ng/mL, p=0.003, white blood cell count 11 9;13 vs. 15 10;19 × 109/L; p=0.035, procalcitonin 0.06 0.05;0.28 vs. 0.69 0.10;2,48 ng/mL, p=0.001 and higher pH 7.4 7.3;7.5 vs. 7.2 7.0;7.4, p=0.012 in blood gas analysis when compared with ACS-CS. There were no significant differences in the severity of the shock according to Society for Cardiovascular Angiography and Interventions (SCAI) SHOCK classification among the groups: from C: 1 (6%) vs. 6 (10%), D: 11 (69%) vs. 27 (42%), E: 4 (25%) vs. 31 (48%), respectively for non-ACS vs. ACS-shock. The non-ACS-CS was more often treated with V-A ECMO 10 (63%) vs. 20 (32%) in ACS-CS, p=0.024. The overall number of in-hospital deaths was 57 (71%). The non-ACS-CS group had significantly lower in-hospital mortality 8 (50%) compared to the ACS-CS patients 49 (77%), p=0.034. Conclusion Patients experiencing non-ACS-CS were younger, have lower levels of inflammatory markers and a higher pH in blood gas analysis at admission. Despite more favourable biomarker profile non-ACS-CS group was treated more aggressively and had significantly lower in-hospital mortality rates when compared with patients facing ACS-CS, which indicates the need to look at CS differently depending on its aetiology.